Alerta

一种ALKBH5在抑制结直肠癌PHF20表达中的用途

Resumen de: CN120695207A

本发明提出了一种ALKBH5在抑制结直肠癌PHF20表达中的用途，包括以下步骤：步骤一：选择合适ALKBH5过表达载体、并敲低PHF20、使用ALKBH5小分子激活剂或CRISPR、Cas9系统调控ALKBH5活性，从而显著抑制结直肠癌细胞的增殖和转移；步骤二：将调控元件递送至结直肠癌细胞或肿瘤组织，递送方式包括病毒载体、脂质体、局部注射或静脉注射，以提高治疗的精确性和有效性；步骤三：检测ALKBH5与PHF20表达水平的变化，评估肿瘤增殖、转移或耐药性的抑制效果。本发明核心在于证实ALKBH5抑制结直肠癌细胞中PHF20表达的作用，通过多种调控手段和递送系统，实现对结直肠癌细胞的增殖、转移和耐药性的抑制。此外，还提供了相应的药物组合物及诊断评估方法，为结直肠癌的治疗和预后提供了新的策略。

自组装纳米颗粒及制备方法和应用、外泌体包裹的纳米材料及应用

Resumen de: CN120694984A

本发明公开了一种自组装纳米颗粒及制备方法和应用、包含自组装纳米颗粒的外泌体包裹的纳米材料及应用，其中自组装纳米颗粒包括五味子酚和绿原酸，所述五味子酚和绿原酸混合形成纳米颗粒。本申请通过五味子酚和绿原酸自组装形成纳米颗粒，自组装纳米颗粒具备优异的抗氧化性能，自组装纳米颗粒被外泌体包裹形成纳米材料，纳米材料能够治疗肝损伤，促进特异性免疫耐受的形成。

一种雨生红球藻外泌体包埋类胡萝卜素的制备方法

Resumen de: CN120695198A

本申请设计了一种雨生红球藻外泌体包埋类胡萝卜素的制备方法，包括步骤S1、将雨生红球藻藻种接种于基础培养基进行育种培养并扩增；步骤S2、对基础培养基进行离心分离，并进行过滤浓缩获取雨生红球藻外泌体；步骤S3、将类胡萝卜素用二甲基亚砜或丙二醇溶解后，将雨生红球藻外泌体与类胡萝卜素混合，于32～40℃自然孵育1～4h，得到含有外泌体的类胡萝卜素。通过上述设计，本申请能够首次利用雨生红球藻外泌体作为载体包埋类胡萝卜素，显著提升脂溶性活性成分的稳定性和生物利用度，虾青素包封率达0.071％、岩藻黄素包封率达2.87％，且工艺全程可规模化操作，在医药、化妆品及功能食品领域具有广阔工业化应用前景。

包含用于在没有任何佐剂的情况下经由阳离子多糖纳米颗粒递送灭活的完整细菌的系统的疫苗组合物

Resumen de: MX2025009500A

The invention relates to the field of vaccine compositions. The invention more particularly relates to a prophylactic vaccine composition that is intended for mammals and birds and comprises a killed whole bacterium, said bacterium being covered with a cationic agent, in particular cationic nanoparticles.

一种铈基靶向纳米药物及其应用和制备方法

Resumen de: CN120695167A

本发明公开了一种铈基靶向纳米药物及其应用和制备方法。本发明通过无载体配位驱动自组装技术，将水溶性葡萄糖氧化酶溶液和铈离子溶液与脂溶性替拉扎明溶液混合在一起，并通过官能团配位键获得无载体配位自驱动的铈基靶向纳米药物。本发明进一步通过反复冻融和差速离心方式高效制备了血小板膜，将其与铈基靶向纳米药物通过共挤出方式制备得到血小板膜仿生铈基靶向纳米药物，能够有效增强铈基靶向纳米药物的靶向性和生物安全性。本发明制备的药物稳定性好，具有优异的生物相容性、低毒性、高靶向性和高肿瘤杀伤性。

一种具有解毒功能的黄芩苷酵母微胶囊及其制备方法和应用

Resumen de: CN120694967A

本发明属于生物制药领域，具体涉及一种具有解毒功能的黄芩苷酵母微胶囊及其制备方法和应用。通过薄膜水化和酸碱‑有机制备出搭载黄芩苷的阳离子脂质体及酵母细胞壁，两者静电自沉积形成黄芩苷酵母微胶囊。实验表明本发明所述的黄芩苷酵母微胶囊可通过改善肾脏纤维化、机体炎症反应及促进毒素排出等途径改善了毒素对机体的损伤。本发明为黄芩苷的低生物利用度提供了一种纳米载体的改善策略，为黄芩苷改善赭曲霉毒素A造成的肾损伤提供科学依据。

一种用于肾损伤的纳米硒制剂及其制备方法和应用

Resumen de: CN120694969A

本发明涉及一种用于肾损伤的纳米硒制剂及其制备方法和应用，所述纳米硒制剂包括芯和壳，所述芯包括硒，所述壳包括二硬脂酰基磷脂酰乙醇胺‑聚乙二醇，所述壳包裹于所述芯的表面。制备方法包括如下步骤：包裹：将芯的原料、壳的原料分别溶于溶剂，得到芯材溶液、壳材溶液；将芯材溶液与壳材溶液混合，使壳的原料包裹于芯的原料的表面，得到含有纳米硒制剂前体的溶液；制备用于肾损伤的纳米硒制剂：将含有纳米硒制剂前体的溶液蒸干，加水重悬，得到用于肾损伤的纳米硒制剂。本发明的纳米硒制剂对AKI有较好的保护作用，具有良好的肾靶向性和生物安全性，能有效改善肾功能，减少肾组织病理学损伤，显著减轻线粒体损伤和细胞凋亡，具有剂量依赖性。

一种透明质酸-柚皮素自组装纳米颗粒的制备方法及应用

Resumen de: CN120694957A

本发明公开了一种抗肿瘤的透明质酸‑柚皮素自组装纳米颗粒的制备方法，属于医药领域。该方法通过透明质酸上的羧基与柚皮素上的羟基结合形成酯基，得到透明质酸‑柚皮素聚合物来进行。亲水性的透明质酸结合疏水性的柚皮素，形成亲疏水性聚合物，然后在水溶液中通过超声波的作用，疏水端排斥水分子而相互聚集，亲水端便包裹在疏水端外围，与水接触，从而形成内核是疏水性的柚皮素，外核是亲水性的透明质酸的纳米粒子。该纳米粒子的粒径为140~200nm，粒子稳定、均匀，体外释放实验结果说明能缓慢释放，细胞实验显示制剂能明显提高柚皮素对肿瘤细胞的毒性，说明其有良好的抗肿瘤活性。

一种负载乏氧前药的上转换纳米颗粒的制备方法与应用

Resumen de: CN120694966A

本发明涉及一种负载乏氧前药的上转换纳米颗粒的制备方法与应用。纳米颗粒由基于上转换纳米颗粒的纳米晶体与有机光敏剂复合，负载甘草酸和乏氧前药后组成。制备方法包含上转换纳米颗粒的制备，有机光敏剂的复合，甘草酸和乏氧前药的负载。本发明制备方法简单，能够有效负载光敏剂和乏氧前药，在808nm近红外光照射下具有高效的光动力治疗性能。甘草酸使纳米颗粒功能化靶向线粒体，光动力治疗引起的乏氧环境激活乏氧前药，引起肿瘤细胞的DNA损伤。进一步引起肿瘤免疫原性细胞死亡，增敏免疫检查点抑制剂的肿瘤免疫治疗疗效，为肿瘤免疫治疗提供新策略。

牡荆素在制备弱精症药物中的应用

Resumen de: CN120694987A

本发明公开了牡荆素在制备弱精症药物中的应用，具体是以人类重链铁蛋白HFn纳米笼负载牡荆素VI形成HFn@VI纳米颗粒，用于制备弱精症药物。本发明统一了牡荆素的药理学和诊断潜力，为男性不育症的精准医学提供一个新的平台。

可用于增溶膜蛋白的脂质纳米盘

Resumen de: AU2024209122A1

Provided herein are composition including lipids and copolymers in the form of a nanodisc assembly. The copolymers include monomer units of methacrylic acid and styrene. Also provided herein is an aqueous solution comprising the subject composition, methods of producing the nanodisc assembly. Further provided are methods of solubilising hydrophobic constituents such as membrane proteins in aqueous solution, including forming nanodisc assemblies of a lipid, the hydrophobic constituent, and the subject copolymer.

一种以融合前构象GPC为靶标的拉沙病毒mRNA疫苗及其制备方法

Resumen de: CN120695172A

本发明提供一种以融合前构象GPC为靶标的拉沙病毒mRNA疫苗及其制备方法，涉及疫苗制备技术领域。所述拉沙病毒mRNA疫苗的氨基酸序列如SEQ ID NO.1所示，核酸序列如SEQ ID NO.2所示，且该疫苗为通过确定拉沙病毒的保守GPC氨基酸序列，并编码融合前构象GPC的氨基酸序列得到。本发明克服了现有技术的不足，能够设计并制备一款对LASV感染具有较好预防效果且安全稳定，研发周期短，成本低的疫苗。

一种规避人体预存抗PEG抗体的方法

Resumen de: WO2024148785A1

A method for evading a preexisting anti-PEG antibody in a human body, and the use of a PEGylated nano-carrier containing terminal hydroxyl in the preparation of a drug for evading a preexisting anti-PEG antibody in the human body. A PEGylated nano-carrier and nano-preparation containing terminal hydroxyl are included. The PEGylated nano-carrier and nano-preparation containing terminal hydroxyl have low binding with the preexisting anti-PEG antibody in the human body, and can thus evade being quickly cleared from the blood of the human body, so as to have a better treatment effect. In addition, by means of evading binding of the PEGylated nano-carrier and the nano-preparation containing terminal hydroxyl to the preexisting anti-PEG antibody in human blood, complement activation can be reduced, and side effects such as clinical injection reaction are reduced.

用于药物用途的RNA制剂

Resumen de: AU2024210882A1

The present disclosure relates to RNA comprising one or more miRNA binding sequences, wherein the one or more miRNA binding sequences bind to miRNA that is present in cells in which expression of the RNA is not desired. Delivering the RNA to cells after administration, in particular after intramuscular or intravenous administration, allows expression of a polypeptide encoded by the RNA in certain cells while expression in other cells is repressed. In some embodiments, such cells comprise endothelial cells. RNA compositions described herein allow expression of a pharmaceutically active peptide or polypeptide by the RNA in a subject while reducing or avoiding the risks of undesired effects resulting from expression of the pharmaceutically active peptide or polypeptide in certain cells or tissues.

脂质化合物、脂质纳米颗粒和药物组合物

Resumen de: CN120698908A

本申请提供了脂质化合物，例如式(I)的化合物。还提供了脂质纳米颗粒和药物组合物，其各自包含脂质化合物，例如下式的化合物。

一种植物来源的挤压纳米囊泡的制备方法和应用

Resumen de: CN120699882A

本发明公开了一种植物来源的挤压纳米囊泡的制备方法和应用，涉及生物医药技术领域。植物来源的挤压纳米囊泡的制备方法包括以下步骤：取洗净的植物根、茎、叶、花或果实榨汁得到植物汁液，用纱布过滤得到第一滤液；将第一滤液经过低速300‑6,000 ×g离心得第二滤液；将第二滤液于0‑5℃下依次经过8,000‑20,000 ×g离心0.5‑3 h，得到第一沉淀；将第一沉淀加至缓冲液中，超声，稀释，依次通过孔径0.4‑10 μm和孔径0.1‑0.4 μm的滤膜，得到第三滤液；将第三滤液离心，取沉淀重悬，得到挤压纳米囊泡。经实验检测，发现上述挤压囊泡特征与天然囊泡相似，但产量远远高于天然囊泡，可作为纳米载体应用于基础或临床。

脂质纳米粒、靶向脂质纳米粒及制备方法和应用

Resumen de: CN120694968A

本发明公开了一种脂质纳米粒、靶向脂质纳米粒及制备方法和应用。该脂质纳米粒具有核壳结构，内核为由含药物分子的PLGA纳米粒形成，外壳为由包括磷脂、胆固醇和修饰材料的原料形成；其中，含药物分子的PLGA纳米粒为由包括PLGA和药物分子的原料形成；PLGA与磷脂的质量比为1～5:1；磷脂与胆固醇的质量比为3～10:1，磷脂与修饰材料的质量比为3～10:1；药物分子选自难溶性药物、水溶性药物、基因和蛋白质中的一种或多种；所述修饰材料为PEG‑DSPE。本发明的脂质纳米粒的硬度可以调控，可以通过调控硬度以改善细胞摄取；本发明的靶向脂质纳米粒可以更好地改善细胞摄取，促进肠上皮细胞吸收，提高口服疗效。

HYDROPHOBIN-BASED CAPSULES WITH TARGET-SENSITIVE RELEASE MECHANISM, COMPOSITIONS COMPRISING THEREOF, AND RELATED METHODS

Resumen de: WO2025196666A2

The present invention relates to hydrophobin (HFB) fusion polypeptides, HFB-based capsules comprising said HFB fusion polypeptides and having a target-sensitive opening mechanism, and compositions comprising the HFB-based capsules. The invention further relates to the use of said HFB capsules as a platform for the delivery of a variety of compounds for agronomical, gastronomical and/or pharmaceutical purposes and its use for the detection of pathogens and/or microbes.

MICROFLUIDIC PREPARATION OF DUAL-PHASE NANODROPLETS WITH FLUORINATED COMPOUNDS

Resumen de: US2025295818A1

The present invention relates to calibrated dual-phase nanodroplets comprising an outer layer and an inner core, said outer layer comprising a biocompatible fluorinated surfactant and said inner core comprising a fluorinated compound and a biocompatible oil. The invention further relates to a method of preparation of said calibrated dual-phase nanodroplets through microfluidic technique, and to their use for in vivo or in vitro diagnostic and/or for therapy.

NOVEL AMYLOID-BETA AGGREGATE DEGRADER AND BRAIN-TARGETING DRUG DELIVERY SYSTEM USING SAME

Resumen de: US2025295612A1

The present invention comprises: a novel molecule capable of disaggregating amyloid-beta plaques; and a brain-targeting amyloid-beta plaque disaggregation nano platform loaded with the molecule. An amyloid-beta plaque disaggregating agent developed according to the present invention exhibits high amyloid-beta plaque disaggregation efficacy, and the brain-targeting amyloid-beta plaque disaggregation nano platform shows high potential in the medical field on the basis of the effects of effectively targeting the brain and disaggregating amyloid-beta plaques present in the brain.

BIOSOLUBLE POLYMER OR PARTICLE FOR DELIVERY OF AN ACTIVE AGENT AND A METHOD FOR THE PRODUCTION

Resumen de: US2025295606A1

The present invention refers to a method for producing a polymer in form of a gel or a particle, and to the resulting polymer, gel and particle, respectively. The polymer comprises a carbon donor and a metal oxide precursor, a metal oxide or a combination thereof and optionally an active agent. The invention is further directed to a composition and film comprising such polymer, and their use as a medicament for example in treating diabetes, obesity, neuronal disease, viral infection or cancer.

IN VIVO NICKASE-BASED EDITING OF THE LPA GENE FOR TREATMENT OF CARDIOVASCULAR DISEASE

Resumen de: WO2024197065A2

Provided herein are gene editing systems and compositions directed to effectuate in vivo edits in the LPA gene. Treatment or prevention of cardiovascular disease through disruption of the production of apo(a) through genetic editing and the reduction of the blood lipoprotein(a) Lp(a) concentration is disclosed herein. Disclosed are nickase-based gene editing systems designed to effectuate the installation of insertions and/or deletions (indel variants) and/or non-synonymous variants in the coding sequence of LPA. The nickase-based gene editing systems generally comprise one or more mRNAs that encode one or more nickases and a plurality of guide oligonucleotides (e.g., gRNAs) and may be delivered in vivo to a mammalian subject in need thereof via a suitable delivery system, such as lipid nanoparticles (LNPs) (with or without GalNAc targeting moieties) intravenously, or otherwise, administered to a patient as potentially a once-and-done therapeutic. The manufacturing, use, and formulation of the gene editing systems and compositions are also disclosed.

POLYMER-DRUG CONJUGATE, INTERMEDIATE THEREOF, AND USE THEREOF

Resumen de: AU2024261935A1

A nano-size controllable and stable polymer-drug conjugate, an intermediate thereof, and a use thereof. Provided is a polymer-drug conjugate as represented by formula (I) and having different polymer bodies, a controllable coupled group quantity, controllable group coupling sites and a controllable nano-size. The drug conjugate has one or more of the following advantages: a low renal clearance rate, a low liver-spleen clearance rate, long plasma half-life, strong drug accumulation capability at lesion tissues, strong drug permeability at lesion tissues, low toxic and side effects, and an excellent treatment effect.

NOVEL LIPID NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACIDS

Resumen de: AU2024233180A1

The present invention provides novel ionizable lipids and novel lipid nanoparticles comprising messenger RNA (mRNA) useful for the delivery of nucleic acids, related pharmaceutical compositions or vaccines as defined herein for use in human or veterinary medicine, in particular for use in the treatment and/or prophylaxis of cancer diseases.

METHOD FOR TRANSIENT ACIDIFICATION OF WOUNDS

Nº publicación: AU2024228558A1 25/09/2025

Solicitante:

EARTH SCIENCE LABORATORIES INC
EARTH SCIENCE LABORATORIES, INC

Resumen de: AU2024228558A1

This disclosure provides the use of nanoparticles of self-assembled acidic molecular clusters (NP-AMCs) of ammonium salts to lower the pH of skin and underlying tissue of a human or other mammal as a means of stimulating the localized immune response to a wound.